{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T04:16:44Z","timestamp":1746159404447,"version":"3.40.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2014,2,26]],"date-time":"2014-02-26T00:00:00Z","timestamp":1393372800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Angiogenesis"],"DOI":"10.1007\/s10456-014-9422-9","type":"journal-article","created":{"date-parts":[[2014,2,25]],"date-time":"2014-02-25T10:44:55Z","timestamp":1393325095000},"source":"Crossref","is-referenced-by-count":3,"title":["Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer"],"prefix":"10.1007","author":[{"given":"William","family":"Cruz-Mu\u00f1oz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Di Desidero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Luz","family":"Jaramillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kae","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Banville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen D.","family":"O\u2019Connor-McCourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Kerbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,2,26]]},"reference":[{"issue":"6","key":"9422_CR1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","volume":"4","author":"RS Kerbel","year":"2004","unstructured":"Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4(6):423\u2013436","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"9422_CR2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrclinonc.2010.82","volume":"7","author":"E Pasquier","year":"2010","unstructured":"Pasquier E, Kavallaris M, Andre N (2010) Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7(8):455\u2013465","journal-title":"Nat Rev Clin Oncol"},{"issue":"19","key":"9422_CR3","doi-asserted-by":"crossref","first-page":"6845","DOI":"10.1158\/0008-5472.CAN-04-2116","volume":"64","author":"A Rapisarda","year":"2004","unstructured":"Rapisarda A et al (2004) Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 64(19):6845\u20136848","journal-title":"Cancer Res"},{"issue":"7","key":"9422_CR4","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1073\/pnas.0812801106","volume":"106","author":"K Lee","year":"2009","unstructured":"Lee K et al (2009) Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci USA 106(7):2353\u20132358","journal-title":"Proc Natl Acad Sci USA"},{"issue":"18","key":"9422_CR5","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.1158\/0008-5472.CAN-09-0167","volume":"69","author":"C Folkins","year":"2009","unstructured":"Folkins C et al (2009) Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res 69(18):7243\u20137251","journal-title":"Cancer Res"},{"issue":"7","key":"9422_CR6","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/labinvest.2012.65","volume":"92","author":"I Martin-Padura","year":"2012","unstructured":"Martin-Padura I et al (2012) Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Lab Invest 92(7):952\u2013966","journal-title":"Lab Invest"},{"issue":"7","key":"9422_CR7","first-page":"1878","volume":"60","author":"T Browder","year":"2000","unstructured":"Browder T et al (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60(7):1878\u20131886","journal-title":"Cancer Res"},{"issue":"8","key":"9422_CR8","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1172\/JCI8829","volume":"105","author":"G Klement","year":"2000","unstructured":"Klement G et al (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105(8):R15\u2013R24","journal-title":"J Clin Invest"},{"issue":"10","key":"9422_CR9","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1158\/1535-7163.MCT-09-0583","volume":"8","author":"LG Daenen","year":"2009","unstructured":"Daenen LG et al (2009) Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models. Mol Cancer Ther 8(10):2872\u20132881","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"9422_CR10","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2005-04-1422","volume":"106","author":"Y Shaked","year":"2005","unstructured":"Shaked Y et al (2005) Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 106(9):3058\u20133061","journal-title":"Blood"},{"issue":"10","key":"9422_CR11","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrc1187","volume":"3","author":"GL Semenza","year":"2003","unstructured":"Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10):721\u2013732","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"9422_CR12","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1158\/0008-5472.CAN-05-4411","volume":"66","author":"R Munoz","year":"2006","unstructured":"Munoz R et al (2006) Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 66(7):3386\u20133391","journal-title":"Cancer Res"},{"issue":"4","key":"9422_CR13","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1158\/1535-7163.MCT-09-0960","volume":"9","author":"K Hashimoto","year":"2010","unstructured":"Hashimoto K et al (2010) Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther 9(4):996\u20131006","journal-title":"Mol Cancer Ther"},{"issue":"16","key":"9422_CR14","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.4161\/cbt.8.16.9004","volume":"8","author":"WM Merritt","year":"2009","unstructured":"Merritt WM et al (2009) Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther 8(16):1596\u20131603","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"9422_CR15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1593\/neo.101174","volume":"13","author":"U Emmenegger","year":"2011","unstructured":"Emmenegger U et al (2011) Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia 13(1):40\u201348","journal-title":"Neoplasia"},{"issue":"3\u20134","key":"9422_CR16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10911-012-9266-0","volume":"17","author":"RS Kerbel","year":"2012","unstructured":"Kerbel RS (2012) Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer. J Mammary Gland Biol Neoplasia 17(3\u20134):229\u2013239","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"10","key":"9422_CR17","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/sj.bjc.6604352","volume":"98","author":"G Bocci","year":"2008","unstructured":"Bocci G et al (2008) Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer 98(10):1619\u20131629","journal-title":"Br J Cancer"},{"issue":"14","key":"9422_CR18","doi-asserted-by":"crossref","first-page":"5885","DOI":"10.1158\/0008-5472.CAN-09-0700","volume":"69","author":"J Shen","year":"2009","unstructured":"Shen J et al (2009) Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. Cancer Res 69(14):5885\u20135892","journal-title":"Cancer Res"},{"issue":"7","key":"9422_CR19","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/bmc.1173","volume":"23","author":"KE Hubbard","year":"2009","unstructured":"Hubbard KE et al (2009) Application of a highly specific and sensitive fluorescent HPLC method for topotecan lactone in whole blood. Biomed Chromatogr 23(7):707\u2013713","journal-title":"Biomed Chromatogr"},{"issue":"8","key":"9422_CR20","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1158\/0008-5472.CAN-06-4238","volume":"67","author":"C Folkins","year":"2007","unstructured":"Folkins C et al (2007) Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 67(8):3560\u20133564","journal-title":"Cancer Res"},{"key":"9422_CR21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1755-8794-2-18","volume":"2","author":"H Mizuno","year":"2009","unstructured":"Mizuno H, Kitada K, Nakai K, Sarai A (2009) PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics 2:18","journal-title":"BMC Med Genomics"},{"issue":"2","key":"9422_CR22","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1054\/bjoc.2001.1907","volume":"85","author":"MC McFadyen","year":"2001","unstructured":"McFadyen MC et al (2001) Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br J Cancer 85(2):242\u2013246","journal-title":"Br J Cancer"},{"issue":"1","key":"9422_CR23","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","volume":"26","author":"AA Garcia","year":"2008","unstructured":"Garcia AA et al (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26(1):76\u201382","journal-title":"J Clin Oncol"},{"issue":"30","key":"9422_CR24","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1200\/JCO.2008.17.4789","volume":"26","author":"S Dellapasqua","year":"2008","unstructured":"Dellapasqua S et al (2008) Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26(30):4899\u20134905","journal-title":"J Clin Oncol"},{"issue":"22","key":"9422_CR25","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1200\/JCO.2005.04.5773","volume":"24","author":"A Bottini","year":"2006","unstructured":"Bottini A et al (2006) Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 24(22):3623\u20133628","journal-title":"J Clin Oncol"},{"key":"9422_CR26","doi-asserted-by":"crossref","first-page":"Abstr 3502","DOI":"10.1200\/jco.2013.31.15_suppl.3502","volume":"31","author":"M Koopman","year":"2013","unstructured":"Koopman M et al (2013) Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): the phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 31:Abstr 3502","journal-title":"J Clin Oncol"},{"issue":"17","key":"9422_CR27","first-page":"1638","volume":"366","author":"GL Miklos","year":"2012","unstructured":"Miklos GL (2012) Bevacizumab in neoadjuvant treatment for breast cancer. N Engl J Med 366(17):1638 (author reply 1639\u201340)","journal-title":"N Engl J Med"},{"issue":"4","key":"9422_CR28","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJMe1113368","volume":"366","author":"AJ Montero","year":"2012","unstructured":"Montero AJ, Vogel C (2012) Fighting fire with fire: rekindling the bevacizumab debate. N Engl J Med 366(4):374\u2013375","journal-title":"N Engl J Med"},{"issue":"11","key":"9422_CR29","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1002\/cncr.26579","volume":"118","author":"S Dawood","year":"2012","unstructured":"Dawood S et al (2012) The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy. Cancer 118(11):2780\u20132786","journal-title":"Cancer"},{"issue":"3","key":"9422_CR30","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10549-011-1685-x","volume":"129","author":"K Aogi","year":"2011","unstructured":"Aogi K et al (2011) First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study. Breast Cancer Res Treat 129(3):829\u2013838","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"9422_CR31","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000336892","volume":"82","author":"C Thomssen","year":"2012","unstructured":"Thomssen C et al (2012) First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study. Oncology 82(4):218\u2013227","journal-title":"Oncology"},{"issue":"1","key":"9422_CR32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10549-011-1695-8","volume":"130","author":"I Smith","year":"2011","unstructured":"Smith I et al (2011) Final overall survival results and effect of prolonged (\u22651\u00a0year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial. Breast Cancer Res Treat 130(1):133\u2013143","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"9422_CR33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10549-010-0788-0","volume":"121","author":"CH Barrios","year":"2010","unstructured":"Barrios CH et al (2010) Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 121(1):121\u2013131","journal-title":"Breast Cancer Res Treat"},{"key":"9422_CR34","doi-asserted-by":"crossref","first-page":"LBA 1010","DOI":"10.1200\/jco.2010.28.18_suppl.lba1010","volume":"28","author":"J Bergh","year":"2011","unstructured":"Bergh J, Greil R, Voytko N (2011) Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). J Clin Oncol 28:LBA 1010","journal-title":"J Clin Oncol"},{"issue":"4","key":"9422_CR35","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1158\/1535-7163.MCT-09-0967","volume":"9","author":"WM Merritt","year":"2010","unstructured":"Merritt WM et al (2010) Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther 9(4):985\u2013995","journal-title":"Mol Cancer Ther"},{"issue":"17","key":"9422_CR36","doi-asserted-by":"crossref","first-page":"5656","DOI":"10.1158\/1078-0432.CCR-11-0078","volume":"17","author":"S Kumar","year":"2011","unstructured":"Kumar S et al (2011) Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin Cancer Res 17(17):5656\u20135667","journal-title":"Clin Cancer Res"},{"key":"9422_CR37","doi-asserted-by":"crossref","unstructured":"Hackl C et al (2013) Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut 62(2):259\u2013271","DOI":"10.1136\/gutjnl-2011-301585"},{"issue":"9","key":"9422_CR38","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1089\/ten.tec.2011.0098","volume":"17","author":"F Goh","year":"2011","unstructured":"Goh F, Sambanis A (2011) In vivo noninvasive monitoring of dissolved oxygen concentration within an implanted tissue-engineered pancreatic construct. Tissue Eng Part C Methods 17(9):887\u2013894","journal-title":"Tissue Eng Part C Methods"},{"key":"9422_CR39","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa032792","volume":"350","author":"H Kato","year":"2004","unstructured":"Kato H et al (2004) A randomized trial of adjuvant chemotherapy with Uracil\u2013Tegafur for adenocarcinoma of the lung. New Engl J Med 350:1713\u20131721","journal-title":"New Engl J Med"},{"key":"9422_CR40","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","volume":"26","author":"Garcia","year":"2008","unstructured":"Garcia et al (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and princess Margaret hospital phase II consortia. J Clin Oncol 26:76\u201382","journal-title":"J Clin Oncol"},{"key":"9422_CR41","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1200\/JCO.2008.17.4789","volume":"26","author":"Dellapasqua","year":"2008","unstructured":"Dellapasqua et al (2008) Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26:4899\u20134905","journal-title":"J Clin Oncol"},{"key":"9422_CR42","first-page":"6891","volume":"48","author":"HH Berendsen","year":"1988","unstructured":"Berendsen HH et al (1988) Characterization of three small cell lung cancer cell lines established from one patient during longitudinal follow-up. Cancer Res 48:6891\u20136899","journal-title":"Cancer Res"},{"key":"9422_CR43","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nrclinonc.2013.158","volume":"10","author":"Kuczynski","year":"2013","unstructured":"Kuczynski et al (2013) Drug rechallenge and treatment beyond progression in oncology: examples, mechanisms and implications of reversible drug resistance. Nature Rev Clin Oncol 10:571\u2013587","journal-title":"Nature Rev Clin Oncol"},{"issue":"2","key":"9422_CR44","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0022-3565(24)38762-2","volume":"296","author":"B Rochat","year":"2001","unstructured":"Rochat B et al (2001) Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther 296(2):537\u2013541","journal-title":"J Pharmacol Exp Ther"},{"issue":"22","key":"9422_CR45","first-page":"6698","volume":"62","author":"R Wittig","year":"2002","unstructured":"Wittig R et al (2002) Candidate genes for cross-resistance against DNA-damaging drugs. Cancer Res 62(22):6698\u20136705","journal-title":"Cancer Res"},{"issue":"2","key":"9422_CR46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10549-010-0735-0","volume":"124","author":"SE Oshita","year":"2010","unstructured":"Oshita SE et al (2010) The small heat shock protein HspB2 is a novel anti-apoptotic protein that inhibits apical caspase activation in the extrinsic apoptotic pathway. Breast Cancer Res Treat 124(2):307\u2013315","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"9422_CR47","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/sj.bjc.6602962","volume":"94","author":"S Langbein","year":"2006","unstructured":"Langbein S et al (2006) Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer 94(4):578\u2013585","journal-title":"Br J Cancer"}],"container-title":["Angiogenesis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-014-9422-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10456-014-9422-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-014-9422-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T22:47:38Z","timestamp":1746139658000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10456-014-9422-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,26]]},"references-count":47,"alternative-id":["9422"],"URL":"https:\/\/doi.org\/10.1007\/s10456-014-9422-9","relation":{},"ISSN":["0969-6970","1573-7209"],"issn-type":[{"type":"print","value":"0969-6970"},{"type":"electronic","value":"1573-7209"}],"subject":[],"published":{"date-parts":[[2014,2,26]]}}}